Publicacións nas que colabora con Susana Belén Bravo López (8)

2024

  1. Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)

    Nature Communications

  2. Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)

    Nature Communications

  3. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

    Nature Communications, Vol. 15, Núm. 1

2017

  1. Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer

    Oncogene, Vol. 36, Núm. 5, pp. 652-666

2013

  1. Humanized medium (h7H) allows long-term primary follicular thyroid cultures from human normal thyroid, benign neoplasm, and cancer

    Journal of Clinical Endocrinology and Metabolism, Vol. 98, Núm. 6, pp. 2431-2441

2012

  1. Defining stem cell types: Understanding the therapeutic potential of ESCs, ASCs, and iPS cells

    Journal of Molecular Endocrinology, Vol. 49, Núm. 2

2010

  1. Expression of exogenous proteins and short hairpin RNAs in human primary thyrocytes

    Analytical Biochemistry, Vol. 400, Núm. 2, pp. 219-228

  2. Functional role of the RET dependence receptor, GFRa co-receptors and ligands in the pituitary

    Frontiers of Hormone Research, Vol. 38, pp. 127-138